
Anthem Biosciences Analyst Review 2027: Q2 Profit Beat Keeps Brokers at ₹1,000 to ₹1,050
Updated: 19 Nov 2026 • 1:56 pm
Posted by:

Anthem Biosciences Stock Snapshot (18 Nov 2026 close)
- Current Market Price (CMP): ₹914.35
- 52-Week High / Low: ₹989.10 / ₹579.15
- Market Capitalisation: ₹51,510 crore
- P/E Ratio vs Industry P/E: 83.9 vs 40.1
- Latest Quarter (Q2 FY27) Revenue: ₹652.93 crore
- Latest Quarter (Q2 FY27) Net Profit: ₹211.46 crore
Quick Answer: The Anthem Biosciences analyst review 2027 shows a profit beat and steady brokerage support. Q2 FY27 total income rose about 9% to ₹652.93 crore, EBITDA rose about 24% to ₹330.39 crore and net profit rose about 22% to ₹211.46 crore, ahead of PL Capital's estimate. PL Capital holds Buy with a ₹1,050 target (4 November 2026), JPMorgan holds Buy at ₹1,000 (November 2026) and Jefferies has ₹1,050 (August 2026). At ₹914.35, the Anthem Biosciences share price target 2027 range implies about 9% to 15% upside.
The Anthem Biosciences analyst review 2027 covers a Bengaluru-based contract research, development and manufacturing company, known as a CRDMO, that makes drug ingredients for global pharma and biotech clients. Readers searching for an Anthem Biosciences share price target 2027 will find several named brokerage targets, all of them above the current price.
Anthem Biosciences closed at ₹914.35 on 18 November 2026, about 8% below its 52-week high of ₹989.10 and about 58% above its low of ₹579.15. This Anthem Biosciences analyst review 2027 covers what brokers say, the September quarter and what will drive the Anthem Biosciences stock outlook 2027.
Click Here – Get Free Investment Predictions
What Brokerages Say in the Anthem Biosciences Analyst Review 2027
| Brokerage | Rating | Target Price | Date |
|---|---|---|---|
| PL Capital (Prabhudas Lilladher) | Buy | ₹1,050 | 4 November 2026 |
| JPMorgan | Buy | ₹1,000 | November 2026 |
| Jefferies | Buy | ₹1,050 | August 2026 |
PL Capital's Q2 FY27 note said profit of about ₹210 crore came in well above its estimate of about ₹180 crore, helped partly by making an intermediate in-house that Anthem earlier bought from outside. JPMorgan, which had a ₹900 target in July, moved to ₹1,000 and kept that view after the results.
Jefferies started coverage in August 2026 with a ₹1,050 target. With the stock at ₹914.35, the named brokerage targets in this Anthem Biosciences analyst review 2027 sit between about 9% and 15% above the market price.
Q2 FY27 Results in the Anthem Biosciences Analyst Review 2027
| Quarter | Total Income | EBITDA | Net Profit |
|---|---|---|---|
| Sep 2026 (Q2 FY27) | ₹652.93 crore | ₹330.39 crore | ₹211.46 crore |
| Jun 2026 (Q1 FY27) | ₹443.11 crore | ₹175.46 crore | ₹119.94 crore |
| Mar 2026 (Q4 FY26) | ₹662.15 crore | ₹318.43 crore | ₹189.76 crore |
| Sep 2025 (Q2 FY26) | ₹598.26 crore | ₹266.13 crore | ₹173.43 crore |
Total income rose about 9% from a year ago, while EBITDA rose about 24%, lifting the EBITDA margin to about 51% from about 44%. Net profit grew about 22% to ₹211.46 crore, the highest quarterly profit in the table.
The June quarter was weak because customer shipments shifted into later quarters, and income bounced back by about 47% in September. For the Anthem Biosciences analyst review 2027, the main point is that margins rose even on modest yearly sales growth.
How Anthem Biosciences Makes Money
Anthem works with drug developers from early research through commercial supply.
- Research services: chemistry and biology work for clients' early drug programmes.
- Development and manufacturing: scaling up and producing active ingredients and intermediates under contract.
- Commercial supply: long-term manufacturing for approved molecules.
- Specialty ingredients: fermentation-based products sold separately.
FY26 revenue was about ₹2,280 crore with profit of about ₹592 crore, up from ₹1,930 crore and ₹451 crore in FY25. Operating cash flow jumped to about ₹845 crore in FY26 from ₹271 crore. That track record is the base of this Anthem Biosciences analyst review 2027.
Contract manufacturers earn more as client molecules move from trials into commercial sales, because volumes rise and pricing is locked into longer contracts. That shift is why brokers value the stock at a premium to domestic generic drug makers, and why quarterly results can swing with the timing of large orders.
Shipment timing is the key thing to understand when reading Anthem's quarterly numbers. A few large orders can move from one quarter to the next, which is why the June quarter looked weak and the September quarter strong. Looking at half-year or full-year totals gives a clearer picture than any single quarter, and H1 FY27 profit of about ₹331 crore already equals more than half of the full FY26 profit of about ₹592 crore.
Growth Triggers in the Anthem Biosciences Analyst Review 2027
- Margin strength: EBITDA margin of about 51% in Q2 FY27.
- In-sourcing: making intermediates in-house helped profit beat estimates.
- Capacity: brokers track the new Unit IV greenfield plant for future volumes.
- Molecule pipeline: more client products reaching commercial stage lifts recurring revenue.
- Cash generation: FY26 operating cash flow of about ₹845 crore supports the Anthem Biosciences share price target 2027 case.
Key Risks in the Anthem Biosciences Analyst Review 2027
- Rich valuation: a trailing P/E near 84 against an industry figure of about 40.
- Product concentration: Nomura flagged reliance on a few key products as the main risk.
- Lumpy quarters: the June quarter showed how shipment timing can swing results.
- Client risk: delays or failures in client drug programmes can cut orders.
- Currency and global demand: most business comes from overseas clients, a factor in the Anthem Biosciences analyst review 2027.
Compare Anthem Biosciences With Other Pharma Stocks on the Univest Screener
Anthem Biosciences Analyst Review 2027: Stock at a Glance
| Metric | Value |
|---|---|
| Share Price (18 Nov 2026 close) | ₹914.35 |
| 52-Week High / Low | ₹989.10 / ₹579.15 |
| Market Capitalisation | ₹51,510 crore |
| P/E (TTM) | 83.9 |
| Industry P/E | 40.1 |
| Price to Book | 15.7 |
| Return on Equity | 18.7% |
| Debt to Equity | 0.01 |
| EPS (TTM) | ₹10.90 |
| FY26 Revenue / Net Profit | ₹2,280 crore / ₹592 crore |
The P/E of about 84 is roughly double the industry level, so the stock already prices in strong growth. The balance sheet is almost debt-free. Compared with the Nifty Pharma index, Anthem trades as a premium CRDMO name, which this Anthem Biosciences analyst review 2027 treats as both a strength and a risk.
Shareholding Trend
| Holder | Sep 2025 | Sep 2026 | Change |
|---|---|---|---|
| Promoters | 74.69% | 71.40% | Down 3.29 points |
| Foreign Investors (FII) | 1.67% | 3.79% | Up 2.12 points |
| Domestic Institutions (DII) | 7.22% | 12.10% | Up 4.88 points |
| Public | 16.42% | 12.70% | Down 3.72 points |
Founder Ajay Bhardwaj holds about 42.4% and the promoter group 71.4%. Institutions raised their combined stake from about 8.9% to 15.9% over the year, a positive signal in the Anthem Biosciences analyst review 2027.
What to Watch After the Anthem Biosciences Analyst Review 2027
- Q3 FY27 results: whether income stays above ₹600 crore after the strong September quarter.
- Margins: EBITDA margin holding near 50%.
- Unit IV plant: timing of commercial production.
- New contracts: additions to late-stage and commercial molecules.
- Target revisions: moves above ₹1,050 would lift the Anthem Biosciences share price target 2027 range.
Final Word on the Anthem Biosciences Analyst Review 2027
The Anthem Biosciences analyst review 2027 shows a high-margin CRDMO that beat profit estimates in Q2 FY27, with PL Capital, JPMorgan and Jefferies all holding Buy calls between ₹1,000 and ₹1,050. The main debate is valuation, with the stock near 84 times trailing earnings.
The Anthem Biosciences stock outlook 2027 depends on steady order flow, margins near 50% and new capacity coming on time. Univest does not give a buy or sell call.
Disclaimer: This article is for educational and informational purposes only and is not investment advice or a recommendation to buy, sell or hold any security. Brokerage ratings and target prices quoted here are opinions of third-party research houses; Univest does not endorse them and gives no buy or sell call. Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.
Frequently Asked Questions
What does the Anthem Biosciences analyst review 2027 show?
It shows a strong September quarter. Q2 FY27 net profit rose about 22% to ₹211.46 crore and EBITDA rose about 24% to ₹330.39 crore. EBITDA margin reached about 51%.
What is the Anthem Biosciences share price target 2027 from brokerages?
PL Capital has a ₹1,050 target from 4 November 2026 and JPMorgan has ₹1,000 from November 2026. Jefferies set ₹1,050 in August 2026. Against ₹914.35, these imply about 9% to 15% upside.
Why did Anthem Biosciences profit beat estimates in Q2 FY27?
PL Capital said profit of about ₹210 crore beat its estimate of about ₹180 crore. Part of the gain came from making an intermediate in-house. Margins rose to about 51% from about 44% a year earlier.
Why was the June quarter weak for Anthem Biosciences?
Customer shipments moved into later quarters, so Q1 FY27 income fell to ₹443.11 crore. Profit that quarter was ₹119.94 crore. Income rebounded to ₹652.93 crore in September.
Is Anthem Biosciences stock expensive based on the Anthem Biosciences analyst review 2027?
The trailing P/E is about 84 against an industry P/E of about 40. Price to book is about 15.7. Brokers justify the premium with high margins and a strong CRDMO pipeline.
What risks does the Anthem Biosciences analyst review 2027 highlight?
The main risks are a rich valuation, reliance on a few key products and lumpy shipments. Nomura flagged product concentration as its main concern. Most revenue comes from overseas clients.
What should investors track after the Anthem Biosciences analyst review 2027?
Track whether Q3 FY27 income stays above ₹600 crore with margins near 50%. Watch the Unit IV plant timeline and new client contracts. Any target change above ₹1,050 would matter.
Recent Articles

KRN Heat Exchanger and Refrigeration Share Price Target 2027: 18.3% Upside to Rs 1,132
19 November 2026

KCP Share Price Target 2027: Is Rs 149 Realistic? Bull Case Points to Rs 181
19 November 2026

Hariom Pipe Industries Share Price Target 2027: Can It Reach Rs 495? Base Case at Rs 409
19 November 2026

Gabriel India Share Price Target 2027: 17.0% Upside to Rs 1,772, Bull Case Rs 2,141
19 November 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
KRN Heat Exchanger and Refrigeration Share Price Target 2027: 18.3% Upside to Rs 1,132
KCP Share Price Target 2027: Is Rs 149 Realistic? Bull Case Points to Rs 181
Hariom Pipe Industries Share Price Target 2027: Can It Reach Rs 495? Base Case at Rs 409
Gabriel India Share Price Target 2027: 17.0% Upside to Rs 1,772, Bull Case Rs 2,141
Euro Pratik Sales Share Price Target 2027: What Earnings Say About Rs 209 and Rs 253

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





